Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Receivables - Other: 2023-2025

Historic Receivables - Other for Artiva Biotherapeutics (ARTV) over the last 2 years, with Sep 2025 value amounting to $79,000.

  • Artiva Biotherapeutics' Receivables - Other fell 40.15% to $79,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $79,000, marking a year-over-year decrease of 40.15%. This contributed to the annual value of $146,000 for FY2024, which is 79.83% down from last year.
  • Artiva Biotherapeutics' Receivables - Other amounted to $79,000 in Q3 2025, which was up 163.33% from $30,000 recorded in Q2 2025.
  • Artiva Biotherapeutics' 5-year Receivables - Other high stood at $892,000 for Q2 2024, and its period low was $30,000 during Q2 2025.
  • Its 3-year average for Receivables - Other is $319,571, with a median of $146,000 in 2024.
  • Data for Artiva Biotherapeutics' Receivables - Other shows a maximum YoY slumped of 96.64% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Artiva Biotherapeutics' Receivables - Other stood at $724,000 in 2023, then crashed by 79.83% to $146,000 in 2024, then slumped by 40.15% to $79,000 in 2025.
  • Its Receivables - Other stands at $79,000 for Q3 2025, versus $30,000 for Q2 2025 and $234,000 for Q1 2025.